Beyang Therapeutics closed an oversubscribed Series A to advance its AI drug discovery platform, clinical pipelines, and international teams.
- Amount
- $30M
- Stage
- Series A
- Announced
- 12 August 2026
- Leads
- Legend Capital, Shanghai Healthcare Capital
- Other investors
- China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners, YuanBio Venture Capital
- Use of funds
- Accelerate platform iteration, advance pipeline candidates through clinical and pre-clinical development, expand international R&D and business development teams.
- Checked
- Announced by the company